Cited by 143Pancreatic and Hepatic Oncology ResearchPancreatic function and diabetesPancreatitis Pathology and Treatment

Nr5a2 maintains acinar cell differentiation and constrains oncogenic Kras-mediated pancreatic neoplastic initiation

Open access
von Figura, Guido, Morris, John P, Wright, Christopher V E, Hebrok, Matthias·2014·Gut

Abstract

OBJECTIVES: Emerging evidence from mouse models suggests that mutant Kras can drive the development of pancreatic ductal adenocarcinoma (PDA) precursors from acinar cells by enforcing ductal de-differentiation at the expense of acinar identity. Recently, human genome-wide association studies have identified NR5A2, a key regulator of acinar function, as a susceptibility locus for human PDA. We investigated the role of Nr5a2 in exocrine maintenance, regeneration and Kras driven neoplasia. DESIGN: To investigate the function of Nr5a2 in the pancreas, we generated mice with conditional pancreatic Nr5a2 deletion (PdxCre(late); Nr5a2(c/c)). Using this model, we evaluated acinar differentiation, regeneration after caerulein pancreatitis and Kras driven pancreatic neoplasia in the setting of Nr5a2 deletion. RESULTS: We show that Nr5a2 is not required for the development of the pancreatic acinar lineage but is important for maintenance of acinar identity. Nr5a2 deletion leads to destabilisation of the mature acinar differentiation state, acinar to ductal metaplasia and loss of regenerative capacity following acute caerulein pancreatitis. Loss of Nr5a2 also dramatically accelerates the development of oncogenic Kras driven acinar to ductal metaplasia and PDA precursor lesions. CONCLUSIONS: Nr5a2 is a key regulator of acinar plasticity. It is required for maintenance of acinar identity and re-establishing acinar fate during regeneration. Nr5a2 also constrains pancreatic neoplasia driven by oncogenic Kras, providing functional evidence supporting a potential role as a susceptibility gene for human PDA.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2012-304287

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Heterozygous or homozygous deletion of terminal acinar differentiation factors Ptf1a, Mist1, and Nr5a2 accelerates KRAS-driven tumorigenesis.

    “heterozygous or homozygous deletion of factors associated with terminal acinar differentiation such as Ptf1a, Mist1, and Nr5a2 accelerate KRAS-driven tumorigenesis119–122.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [119]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
von Figura, G., Morris, J. P., Wright, C. V. E., & Hebrok, M.
Affiliations
  • University of California, San Francisco (US)
  • Vanderbilt University (US)
Corresponding author
Hebrok, Matthias
Venue
Gut
Publisher
BMJ
Published
2013-05-03
Volume
63
Issue
4
Pages
656-664
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2169837598
Cited by
143
References
41
Citations by year
2026: 3 · 2025: 3 · 2024: 11 · 2023: 14 · 2022: 2 · 2021: 19 · 2020: 9 · 2019: 13 · 2018: 17 · 2017: 7 · 2016: 12 · 2015: 18 · 2014: 8 · 2013: 7
FWCI
8.21
Type
journal article
Language
en
Open access
Locations
  • Gut (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
Funders
  • University of California, San Francisco
  • National Cancer Institute (R01CA112537)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30-DK-63720, U19DK042502, U01DK089570, P30DK063720)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
Keywords
NR5A2, acinar differentiation, acinar-to-ductal metaplasia, pancreatic ductal adenocarcinoma, oncogenic KRAS, pancreatic neoplasia, pancreatic regeneration, pancreatic precancerous lesions
MeSH terms
Animals, Ceruletide, Cell Differentiation, Cell Line, Cell Transformation, Neoplastic, Pancreatic Neoplasms, Pancreatitis, Proto-Oncogene Proteins p21(ras), Receptors, Cytoplasmic and Nuclear, Carcinoma, Acinar Cell, Carcinoma, Pancreatic Ductal, Mice, Real-Time Polymerase Chain Reaction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review